Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CytomX Therapeutics Inc CTMX

Healthcare Biotechnology
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic... see more

Recent & Breaking News (NDAQ:CTMX)

CytomX Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire November 11, 2020

CytomX Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update

GlobeNewswire November 5, 2020

CytomX Therapeutics Announces Treatment of First Patient in Phase 2 Expansion Study of CX-2029, an Anti-CD71 Probody Drug Conjugate

GlobeNewswire November 5, 2020

CytomX Therapeutics to Announce Third Quarter 2020 Financial Results

GlobeNewswire October 29, 2020

CytomX Therapeutics Announces the Planned Retirement of Chief Scientific Officer, W. Michael Kavanaugh, M.D.

GlobeNewswire October 6, 2020

CytomX Therapeutics Announces New Employment Inducement Grants

GlobeNewswire September 18, 2020

CytomX Therapeutics to Participate in Upcoming Healthcare Conferences

GlobeNewswire September 2, 2020

CytomX Therapeutics Announces Second Quarter 2020 Financial Results and Provides Business Update

GlobeNewswire August 6, 2020

CytomX Therapeutics to Participate in the 2020 Wedbush PacGrow Healthcare Conference

GlobeNewswire August 4, 2020

CytomX Therapeutics to Announce Second Quarter 2020 Financial Results

GlobeNewswire July 28, 2020

FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against CytomX Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA July 20, 2020

CTMX Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against CytomX Therapeutics, Inc. and Lead Plaintiff Deadline: July 20, 2020

Newsfile July 20, 2020

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against CytomX Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile July 20, 2020

FINAL DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against CytomX Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA July 20, 2020

MONDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against CytomX Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA July 18, 2020

FINAL MONDAY DEADLINE: ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Reminds CytomX Therapeutics, Inc. Investors TO CONTACT FIRM BEFORE Important Monday JULY 20 Deadline in Securities Class Action - CTMX

ACCESSWIRE IA July 18, 2020

Lead Plaintiff Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In CytomX Therapeutics, Inc. To Contact The Firm

Newsfile July 17, 2020

DEADLINE MONDAY ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against CytomX Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile July 17, 2020

CTMX FINAL DEADLINE: ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Reminds CytomX Therapeutics, Inc. Investors of Important Monday Deadline in Securities Class Action - CTMX

GlobeNewswire July 17, 2020

FINAL DEADLINE JULY 20: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against CytomX Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA July 16, 2020